New Zealand markets closed

PFE Jan 2024 50.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
21.05-0.48 (-2.23%)
As of 02:43PM EST. Market open.
Full screen
Previous close21.53
Expiry date2024-01-19
Day's range21.05 - 21.17
Contract rangeN/A
Open interest79
  • Business Wire

    Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

    NEW YORK, December 10, 2023--Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR). The findings were presented today at t

  • Motley Fool

    3 Dividend Stocks Trading at 52-Week Lows

    I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap. In today's video I will look at three dividend stocks trading at their 52-week lows and examine their metrics to determine if the stock is cheap or not.

  • Motley Fool

    Is Pfizer Stock a Buy Now?

    Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. Revenue from its COVID-19 products is down big, and investors are concerned about looming patent cliffs for the business in the years ahead. Let's look at what happened -- and Pfizer's prospects for overcoming this latest challenge.